Gefapixant
- Generic Name
- Gefapixant
- Brand Names
- Lyfnua
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19N5O4S
- CAS Number
- 1015787-98-0
- Unique Ingredient Identifier
- 6K6L7E3F1L
- Background
It has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment or unexplained chroni...
- Indication
用于成人治疗难治性慢性咳嗽（RCC）或不明原因慢性咳嗽（UCC）。
- Associated Conditions
- Refractory Chronic Cough, Unexplained Chronic Cough
- Associated Therapies
- -
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 253
- Registration Number
- NCT02612610
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 24
- Registration Number
- NCT02612623
- Locations
- 🇺🇸
Afferent Investigative Site, Greenfield, Wisconsin, United States
A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 51
- Registration Number
- NCT02502097
A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 14
- Registration Number
- NCT02492776
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 6
- Registration Number
- NCT02477709
- Locations
- 🇺🇸
American Health Research, Charlotte, North Carolina, United States
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 50
- Registration Number
- NCT02397460
- Locations
- 🇬🇧
The Medicines Evaluation Unit, Manchester, United Kingdom
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 59
- Registration Number
- NCT02349425
A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 18
- Registration Number
- NCT02229877
The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 107
- Registration Number
- NCT01569438
- Locations
- 🇺🇸
Afferent Investigative Site, Virginia Beach, Virginia, United States
A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 171
- Registration Number
- NCT01554579
- Locations
- 🇺🇸
Afferent Investigative Site, Kenosha, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath